Vericel Corp (VCEL)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Vericel Corp (VCEL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012244
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Vericel Corp (Vericel) formerly Aastrom Biosciences, Inc. is a medical device company that develops patient-specific expanded cellular therapies to repair and regenerate damaged tissue for the treatment of severe, chronic ischemic cardiovascular diseases. It markets two autologous cell therapy products in the US: Carticel, an autologous chondrocyte implant for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement for the treatment of patients with deep-dermal. The company also develops MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee; and ixmyelocel-T, a patient-specific multicellular therapy for the treating advanced heart failure. It has manufacturing facilities in Cambridge, Massachusetts; Ann Harbour, Michigan and Kastrup, Denmark. Vericel is headquartered in Cambridge, the US.

Vericel Corp (VCEL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Vericel Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Vericel Corp, Medical Devices Deals, 2011 to YTD 2017 10
Vericel Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Vericel Corp, Pharmaceuticals & Healthcare, Deal Details 12
Licensing Agreements 12
Innovative Cellular Therapeutics Enters into Licensing Agreement with Vericel 12
Equity Offering 13
Vericel Raises USD19.6 Million in Public Offering of Shares 13
Aastrom Biosciences Raises USD15 Million in Private Placement of Shares 15
Aastrom Biosciences Raises USD40 Million in Public Offering of Shares 16
Aastrom Biosciences Completes Public Offering Of Shares For US$9 Million 18
Aastrom Biosciences Completes Private Placement Of Series B Convertible Preference Stock For US$40 Million 19
Aastrom Biosciences Announces Public Offering Of US$20.3 Million 20
Acquisition 21
Aastrom Biosciences Completes Acquisition of Genzyme Biosurgery from Sanofi for USD6.5 Million 21
Vericel Corp – Key Competitors 22
Vericel Corp – Key Employees 23
Vericel Corp – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Nov 07, 2017: Vericel Reports Third-Quarter 2017 Financial Results 25
Aug 09, 2017: Vericel Reports Second-Quarter 2017 Financial Results 27
May 10, 2017: Vericel Reports First-Quarter 2017 Financial Results 29
Mar 10, 2017: Vericel Reports Fourth-Quarter and Year-End 2016 Financial Results 31
Nov 07, 2016: Vericel Reports Third-Quarter 2016 Financial Results 33
Aug 08, 2016: Vericel Reports Second-Quarter 2016 Financial Results 35
May 10, 2016: Vericel Reports First-Quarter 2016 Financial Results 37
Mar 14, 2016: Vericel Reports Fourth-Quarter and Year-End 2015 Financial Results 38
Corporate Communications 40
Apr 10, 2017: Vericel Announces Appointment of Michael Halpin as Senior Vice President, Quality and Regulatory Affairs 40
Product News 41
09/07/2016: Vericel to Present Data at the American Heart Associations Scientific Sessions 2016 on the Reduction of Ventricular Arrhythmias with Ixmyelocel-T in the ixCELL-DCM Clinical Trial 41
04/04/2016: Cell Therapy May Mend Damaged Hearts, Study Says 42
03/29/2016: Vericel to Host Review of Positive Phase 2b ixCELL-DCM Trial Results Following American College of Cardiology 65th Annual Scientific Sessions 43
03/28/2016: Vericel Announces Publication of Clinical Trial Rationale and Study Design for the Phase 2b ixCELL-DCM Trial of Ixmyelocel-T in Patients with Heart Failure Due to Ischemic Dilated Cardiomyopathy 44
Product Approvals 45
Feb 21, 2017: Vericel Receives FDA Fast Track Designation for Ixmyelocel-T, an Investigational Product for the Treatment of Patients with Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy 45
Clinical Trials 46
Nov 14, 2016: Additional Pre-Specified Secondary Results on the Reduction of Ventricular Arrhythmias Presented at AHA from Vericels Positive Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T 46
Apr 04, 2016: Results from Vericel Positive Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T Presented at ACC and Published in The Lancet 47
Mar 10, 2016: Vericel Announces Positive Top-Line Results From Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T in Patients With Heart Failure Due to Ischemic Dilated Cardiomyopathy 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Vericel Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Vericel Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Vericel Corp, Deals By Therapy Area, 2011 to YTD 2017 9
Vericel Corp, Medical Devices Deals, 2011 to YTD 2017 10
Vericel Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Innovative Cellular Therapeutics Enters into Licensing Agreement with Vericel 12
Vericel Raises USD19.6 Million in Public Offering of Shares 13
Aastrom Biosciences Raises USD15 Million in Private Placement of Shares 15
Aastrom Biosciences Raises USD40 Million in Public Offering of Shares 16
Aastrom Biosciences Completes Public Offering Of Shares For US$9 Million 18
Aastrom Biosciences Completes Private Placement Of Series B Convertible Preference Stock For US$40 Million 19
Aastrom Biosciences Announces Public Offering Of US$20.3 Million 20
Aastrom Biosciences Completes Acquisition of Genzyme Biosurgery from Sanofi for USD6.5 Million 21
Vericel Corp, Key Competitors 22
Vericel Corp, Key Employees 23
Vericel Corp, Other Locations 24
Vericel Corp, Subsidiaries 24

★海外企業調査レポート[Vericel Corp (VCEL)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Realord Group Holdings Limited:企業の戦略・SWOT・財務情報
    Realord Group Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Realord Group Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Star Gas Partners L.P.:企業の戦略・SWOT・財務情報
    Star Gas Partners L.P. - Strategy, SWOT and Corporate Finance Report Summary Star Gas Partners L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Fisher & Paykel Healthcare Corporation Ltd (FPH):企業の財務・戦略的SWOT分析
    Fisher & Paykel Healthcare Corporation Ltd (FPH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key s …
  • IDOX Plc (IDOX):企業の財務・戦略的SWOT分析
    Summary IDOX Plc (IDOX) operates as an information technology company that supplies and develops software solutions and information services. The company offers services such as funding, manages services, government and compliance solutions. Its government services include environmental, legal, demo …
  • Egdon Resources Plc (EDR):企業の財務・戦略的SWOT分析
    Summary Egdon Resources Plc (Egdon) is oil and gas company that offers exploration and production services. The company explores and develops petroleum and natural gas assets in East Midlands, North East England, North West England, and Southern England, the UK. Its project site includes Wressle, No …
  • Inner Mongolia Yili Industrial Group Co Ltd:企業の戦略・SWOT・財務情報
    Inner Mongolia Yili Industrial Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Inner Mongolia Yili Industrial Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • Acorn Energy Inc (ACFN):企業の財務・戦略的SWOT分析
    Acorn Energy Inc (ACFN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • XCyton Diagnostics Ltd-医療機器分野:企業M&A・提携分析
    Summary XCyton Diagnostics Ltd (Xcyton) is a molecular biology company that develops and markets diagnostics products and services. The company provides ELISA kit for the detection of HIV infection; ELISA products for the detection of Neurocysticercosis, Hepatitis C and Japanese encephalitis. It pro …
  • Caretech Holdings Plc (CTH):企業の財務・戦略的SWOT分析
    Summary Caretech Holdings Plc (CareTech) is a children and adult care service provider. The company offers solution for adults and solution for children and young people. its adult care services includes learning disability, mental health, acquired brain injury, eating disorders, sensory impairments …
  • Metalico, Inc.:企業の戦略的SWOT分析
    Metalico, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • London Stock Exchange Group Plc:戦略・SWOT・企業財務分析
    London Stock Exchange Group Plc - Strategy, SWOT and Corporate Finance Report Summary London Stock Exchange Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • DBV Technologies SA (DBV):企業の財務・戦略的SWOT分析
    Summary DBV Technologies SA (DBV Technologies) is a biopharmaceutical company which develops self-administered and non-invasive therapies to treat food allergies and other immunological diseases. Its product pipeline includes Viaskin peanut, Viaskin milk and Viaskin egg indicated for the treatment o …
  • National Life & General Insurance Company SAOC (NLIF):企業の財務・戦略的SWOT分析
    National Life & General Insurance Company SAOC (NLIF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s …
  • Southwestern Electric Power Co:企業の戦略的SWOT分析
    Southwestern Electric Power Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Energy Transfer LP:企業の戦略・SWOT・財務分析
    Energy Transfer LP - Strategy, SWOT and Corporate Finance Report Summary Energy Transfer LP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • ACEA Biosciences Inc:医療機器:M&Aディール及び事業提携情報
    Summary ACEA Biosciences Inc (ACEA) is a biotechnology company that development and commercialization of cell analysis instruments for life science research and clinical diagnostics. The company's products include impedance-based, label-free, and real-time cell analysis systems, benchtop flow cytome …
  • AFC Energy plc (AFC):電力:M&Aディール及び事業提携情報
    Summary AFC Energy plc (AFC Energy) is a developer of alkaline fuel cells. The company's projects include Power-Up and Alkammonia. Its power generation technology is used in the industrial markets and produces heat, water, and electricity. AFC Energy provides its electricity for industrial applicati …
  • Otto Energy Ltd (OEL):石油・ガス:M&Aディール及び事業提携情報
    Summary Otto Energy Ltd (Otto Energy), formerly Ottoman Energy Ltd, is an oil and gas company that offers exploration, production, and development of oil and gas properties. The company's products include oil and gas. It operates its exploration properties located in the Offshore Gulf of Mexico such …
  • ERBA Molecular Ltd:企業の製品パイプライン分析2018
    Summary ERBA Molecular Ltd (ERBA Molecular), formerly Lumora Ltd, a subsidiary of Erba Diagnostics Mannheim GmbH, is a medical equipment company that offers innovative molecular diagnostics. The company provides technology that is used in medical diagnostics, agricultural, livestock and crops, food …
  • Orbit International Corp:企業の戦略・SWOT・財務分析
    Orbit International Corp - Strategy, SWOT and Corporate Finance Report Summary Orbit International Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆